POPH90068 Chap.8 Biomedical Prevention and Resistance
Biomedical Prevention and Resistance
Biomedical prevention decisions require more than an efficacy percentage. Effects can differ across organisms, regimens and populations, while uptake, adherence and companion services determine real-world impact. Antibiotic prophylaxis also raises antimicrobial resistance and stewardship questions that extend beyond the person receiving it.
This chapter builds conditional recommendations with defined eligibility, shared decision-making, infection-specific communication, surveillance and explicit review triggers. It keeps individual benefit and population stewardship visible at the same time.
Study design, precision and represented participants define the evidence boundary, while resistance indicators and delivery outcomes determine whether a monitored program should continue, change or stop.
What this chapter covers
- 01
Efficacy and effectiveness
- 02
Organism-specific effects
- 03
Population eligibility
- 04
Shared decision-making
- 05
Antimicrobial resistance
- 06
Monitoring and review rules
Worked example · free
Write a conditional recommendation
- 1Define eligibility using current clinical guidance and the studied population.
- 1Use shared decision-making and preserve regular testing and treatment.
- 1Communicate organism-specific benefits and incomplete protection.
- 1Monitor safety, antibiotic use, outcomes and resistance with a review trigger.
Key terms
- Prophylaxis
- An intervention used to prevent infection before or after a relevant exposure.
- Antimicrobial resistance
- Reduced susceptibility that can make antimicrobial treatment less effective.
- Stewardship
- Coordinated use of antimicrobials intended to preserve benefit and limit avoidable harm.
- Eligibility
- The defined characteristics that determine who may enter a program.
- Review trigger
- A predefined finding that requires reconsideration or modification of a program.
Biomedical Prevention and Resistance FAQ
Why should effects be reported by organism?
A regimen may perform differently across infections because biology and resistance differ. A broad prevention claim can create false reassurance and weaken other testing or prevention practices.
How should resistance uncertainty be handled?
State what is known and uncertain, monitor resistance and antibiotic exposure, and predefine review or stopping rules. Uncertainty should produce adaptive governance rather than dismissal or overconfidence.
What turns an efficacious tool into a public health program?
The program needs suitable eligibility, delivery, uptake, adherence support, testing, safety management, equitable reach, communication and monitoring. Without those components, study efficacy may not translate into population benefit.
Assessment move
Build a two-column appraisal for every biomedical option: benefits by infection and population on one side, risks and delivery conditions on the other. Add the study design and precision beneath each claim. Then write a recommendation that names eligibility, companion services, monitoring and the finding that would trigger review. Check that messaging does not generalise across organisms or populations.
Finish by identifying who could be excluded or falsely reassured. This structure produces balanced policy answers without reducing the decision to a single effect estimate. Separate four questions that are often blended together: does the option have an effect under the studied conditions, for which outcomes and organisms, in which participants, and under what delivery conditions?
Build an evidence grid with one row per outcome rather than carrying a headline percentage across all infections. Record the comparator, interval and follow-up beside the estimate. If evidence is absent for an organism or population, label it absent; do not substitute evidence from another outcome because the delivery product is the same. Translate trial evidence into a conditional recommendation.
State who was represented, what eligibility needs confirmation, what shared decision must occur and which companion services remain necessary. Include testing, follow-up, prevention counselling or other course-supported elements only where relevant to the scenario. Then identify factors that could reduce real-world impact, such as limited uptake, incomplete use, access barriers or discontinuation.
This prevents efficacy from being presented as automatic population effectiveness. Give antimicrobial resistance its own pathway. Identify antibiotic exposure, possible selection pressure, the organisms or ecological outcomes being monitored and the population scale at which harm may emerge.
Do not imply that an individual benefit automatically outweighs collective stewardship concerns, or that any theoretical resistance risk automatically rules out use. Frame the decision as a balance supported by surveillance, eligibility limits, informed discussion and explicit review triggers. Distinguish evidence observed in the supplied studies from risks that remain uncertain.
Practise message testing with three audiences: an eligible person, a service team and a policy decision-maker. The person needs a balanced explanation of likely benefits, uncertainty, limitations and continued prevention needs. The service team needs an implementable pathway and monitoring responsibilities.
The decision-maker needs population impact, equity, cost or capacity considerations and the evidence threshold for continuation. Check that no version promises protection against outcomes not established by the evidence. Finish with a recommendation paragraph containing decision, population, evidence, conditions, monitoring and boundary. Add one sentence on equitable access and one on the result that would cause revision.
A strong answer may support monitored use, restrict use, request further evidence or advise against implementation depending on the case. Its quality comes from transparent reasoning, not from choosing the most enthusiastic or most cautious conclusion.
